Theme: Atherosclerosis: Its About More Than Heart Disease

Atherosclerosis 2017

Atherosclerosis 2017

Conference series LLC invites you to attend the 2nd Annual Conference on Atherosclerosis and Clinical Cardiology to be held at May 01-03, 2017, Toronto, Canada Atherosclerosis 2017 will bring together world-class professors, scientists and cardiologists to discuss strategies for disease remediation for heart in this cardiology conferenceCardiology meetings are diversified on topics like cardiology congressworld cardiology conferencecardiovascular conference, cardiac surgery conference.

2nd Annual Conference on Atherosclerosis and Clinical Cardiology is designed to provide diverse and current education that will keep medical professionals abreast of the issues affecting the prevention, diagnosis and treatment of Atherosclerosis.

Atherosclerosis is a disease in which plaque builds up inside arteries, blood vessels that carry oxygen-rich blood to heart and other parts of body. Plaque is made up of fat, cholesterol, calcium, and other substances found in the blood. Over time, plaque hardens and narrows arteries. This limits the flow of oxygen-rich blood to your organs and other parts of your body. Atherosclerosis can affect any artery in the body, including arteries in the heart, brain, arms, legs, pelvis, and kidneys. As a result, different diseases may develop based on which arteries are affected.

Conference series LLC Organizes 1000+ Global events  every year across the globe with support from 1000+ more scientific societies and Publishes 500+ Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members. The Cardiology Conferences 2016 have been designed with a wide spectrum.

The Atherosclerosis 2016 will be organized around the theme “Advancements in management of Atherosclerosis ".

Track 1: Atherosclerosis

Atherosclerosis sometimes called hardening of the arteries can slowly narrow and harden the arteries throughout the body. When atherosclerosis affects the arteries of the heart, it’s called coronary artery disease. Heart diseases, such as coronary heart disease, heart attack, high blood pressure are the leading cause of death for men and women. Most of these deaths are from heart attacks caused by sudden blood clots in the heart’s arteries.

Track 2:  Vascular Biology

The vascular network consists of both small and large vessels specifically designed to accommodate varying levels of blood flow and pressure, depending upon the location within the body. When the blockage of these vessels in heart, the risk of cardiovascular diseases are seen,  mostly prone for the diseases like atherosclerosis, clotting of blood and aneurysm. The type of atherosclerosis known as peripheral arterial disease, peripheral vascular disease and lower extremity vascular disease occurs in the vessels that carry blood to the arms.  In healthy arteries, a smooth lining prevents blood from clotting and promotes steady blood flow. In PAD/PVD, the arteries slowly become narrowed or blocked when plaque gradually forms inside the artery walls.

Track 3: Thrombosis

Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. When a blood vessel is injured, the body uses platelets and fibrin to form a blood clot to prevent blood loss. Even when a blood vessel is not injured, blood clots may form in the body under certain conditions. A clot that breaks free and begins to travel around the body is known as an embolus. Thrombosis condition is also one of the cause of atherosclerosis. The thrombosis is of many types like deep vein thrombosis, portal vein thrombosis, renal vein thrombosis, cerebral venous sinus thrombosis. Deep vein thrombosis occurs when a blood clot (thrombus) forms in one or more of the deep veins in your body. Deep vein thrombosis is a serious condition because blood clots in your veins can break loose, travel through your bloodstream and lodge in your lungs, pulmonary embolism.

Track 4: Lipoproteins and Lipid Transport

The plasma lipoproteins are the primary means of transport of cholesterol among tissues. In particular, the Apo B-containing lipoproteins (VLDL, IDL and LDL) are important for the delivery of cholesterol from the liver to peripheral tissues, while HDL appear to mediate the reverse process of movement of cholesterol from tissues back to the liver. Both of these transport processes are necessary for efficient whole body cholesterol homeostasis, because the liver is the major site of both the production and excretion of cholesterol. However, deviations from a proper balance of transport of cholesterol, either increases in LDL levels or decreases in HDL cholesterol flux, may result in accumulation of cholesterol in extra hepatic tissues. Increased risk of atherosclerosis and CHD may be associated with elevation in the number of LDL particles, increase or decrease in LDL particle size, or changes in the composition of plasma LDL.

Track 5: Genetics of Atherosclerosis

Atherosclerosis, the primary cause of coronary artery disease and stroke, is a disorder with multiple genetic and environmental contributions. Genetic-epidemiologic studies have identified a surprisingly long list of genetic and non-genetic risk factors for coronary artery disease. However, such studies indicate that family history is the most significant independent risk factor. Advances in techniques of molecular genetics have revealed that genetic ground significantly influences susceptibility to atherosclerotic vascular diseases. Besides further investigations of monogenetic diseases, candidate genes, genetic polymorphisms, and susceptibility loci associated with atherosclerotic diseases have been identified in recent years, and their number is rapidly increasing.

Track 6: Atherosclerosis Therapeutics

Treatments for atherosclerosis may include heart-healthy lifestyle changes, medicines, and medical procedures or surgery includes, lowering the risk of blood clots forming, preventing atherosclerosis-related diseases, reducing risk factors in an effort to slow or stop the build-up of plaque, relieving symptoms and widening or bypassing plaque-clogged arteries. 

Track 7: Inflammation in Atherosclerosis

Atherosclerosis is a prevalent cardiovascular disease marked by inflammation and the formation of plaque within arterial walls. As the disease progresses, there is an increased risk of major cardiovascular events. Owing to the nature of atherosclerosis, it is imperative to develop methods to further understand the physiological implications and progression of the disease. The combination of positron emission tomography (PET)/computed tomography (CT) has proven to be promising for the evaluation of atherosclerotic plaques and inflammation within the vessel walls.

Track 8: Clinical Trials in Cardiology

Clinical trials in cardiology research investigations are being conducted in which people of cardiac failures or disorders volunteer to test new treatments, interventions or tests as a means to prevent, detect, treat or manage various cardiovascular diseases or medical conditions. Some investigations look at how people respond to a new intervention and the side effects which might occur. This helps to determine if a new intervention works, if it is safe, and if it is better than the interventions that are already available. Clinical trials might also compare existing interventions, test new ways to use or combine existing interventions or observe how people respond to other factors that might affect their health such as dietary changes.

Track 9: Clinical Manifestations of Atherosclerosis

Atherosclerosis does not usually produce symptoms until blood circulation becomes restricted or blocked, leading to cardiovascular disease (CVD). The type of cardiovascular disease and its associated symptoms depends on where the blockage occurs. Conditions caused by atherosclerosis include peripheral arterial disease, angina, aneurysm, heart attack and stroke.

Track 10: Pediatric Cardiology

Pediatric Cardiology is responsible for the diagnosis of congenital heart defects, performing diagnostic procedures such as echocardiograms, cardiac catheterizations and electrophysiology studies. The increasing number of neonates with congenital heart defects referred to the neonatal intensive care unit reflects the increasing awareness that the defects may be present. Chest radiography and ECG rarely assist in the neonatal diagnosis. Congestive heart failure in the fetus, or hydrops, can be detected by performing fetal echocardiography. Many of the pediatric heart defects such as patent ductus arteriosus interruption, vascular ring division, pericardial window, diaphragm placation, thoracic duct ligation, ligation of collateral vessels have been repaired using pediatric interventional cardiology. Apart from these techniques nursing and care for pediatric cardiac patients also plays an important role for the cure of pediatric cardiac patients.

Track 11: Clinical Cardiology

Clinical Cardiology is a specialty of internal medicine. Clinical cardiology is the area where patients are access to specialized inpatient and outpatient heart care and long-term management of their conditions. The clinical cardiology focuses on the diagnosis, medical management (use of medicines), and prevention of cardiovascular disease. Cardiologists are specialized in diagnosing and treating diseases or conditions of the heart and blood vessels and the cardiovascular system.

Track 12: Stroke and Hypertension

Strokes can come on suddenly, stealing the use of an arm or the ability to speak. A stroke can be fatal or leave us permanently disabled. About half of all strokes are caused by atherosclerosis -- the same process of narrowing and hardening of the arteries that causes heart attacks. Atherosclerosis progresses silently, without symptoms, putting our brains and our independence at risk. Reducing the risk factors for atherosclerosis lowers the risk of stroke.

Hypertension is a common condition in which the long-term force of the blood against your artery walls is high enough that it may eventually cause health problems, such as heart disease. Blood pressure is determined both by the amount of blood your heart pumps and the amount of resistance to blood flow in your arteries. The more blood your heart pumps and the narrower your arteries, the higher your blood pressure. In most people with established essential hypertension, increased resistance to blood flow accounts for the high pressure while cardiac output remains normal.

Track 13: Atherosclerosis On-going Research

In the battle against atherosclerosis, the stakes remain high. Atherosclerosis involves inflammation and build-up of fatty plaques, or atheroma within vessel walls, which eventually lead to the hardening and narrowing of the arteries. When an atheroma ruptures, a blood clot can form to trigger a heart attack or stroke. Because development of atherosclerosis in the body is a complex process, researchers are labouring on many fronts to find new ways to understand and treat this serious disease.

Track 14: Advances in Cardiology Education

Advances in Cardiology Education represent the current thinking of international experts regarding the underlying mechanisms of cardiovascular risk and the pathogenesis & pathophysiology of heart and its related disorders. This session gives new insights into the relationship between arterial stiffness, cardiovascular diagnosis, vascular study and atherosclerosis, but also establishes the possible interactions with age and other cardiovascular factors such as high blood pressure, diabetes and hyperlipidemia.

Track 15: Entrepreneur Investment Meet

For sustaining India's rapid economic growth entrepreneurship is the counteractant. Entrepreneur is an individual who, rather than working as an employee, runs a small business and assumes all the risk and reward of a given business venture, idea, or good or service offered for sale. The present conference creates a global platform to interact Entrepreneurs and the Investors globally in the field of cardiology and cardiovascular diseases control, which is going to lead a healthy life ultimately to healthy world.

Track 16: Exemplification of Patients 

Atherosclerosis remains a major cause of death in industrialized countries. In vivo visualization of the atherosclerotic plaque and its components (calcifications, fibro cellular tissue, lipid core, hemorrhage, and thrombus), particularly in humans, will further elucidate the disease process and the effect of various types of interventions, and subsequently will have important clinical implications. Recently, angiography and ultrasound were the most common methods of analyzing atherosclerotic disease. Angiography provides information on the degree of stenosis but only limited information on the morphology of the atherosclerotic plaque. Ultrasound is able to visualize the plaque and to demonstrate the presence of calcifications.

Atherosclerotic cardiovascular disease is the leading cause of mortality worldwide. Atherosclerosis is a disease in which plaque builds up inside arteries, blood vessels that carry oxygen-rich blood to heart and other parts of body. Atherosclerosis can affect any artery in the body, including arteries in the heart, brain, arms, legs, pelvis, and kidneys. As a result, different diseases may develop based on which arteries are affected. Atherosclerosis sometimes called hardening of the arteries which can slowly narrow and harden the arteries throughout the body. When atherosclerosis affects the arteries of the heart, it’s called coronary artery disease.

The committee of 2nd Annual Conference on Atherosclerosis, Vascular Biology and Thrombosis which is to be held during May 01-03, 2016 at Toronto, Canada promises to showcase the top-notch research work on atherosclerosis which is one of the root cause for the heart failure and low functioning of the heart. This conference will bring together world-class professors, scientists and cardiologists to discuss strategies for disease remediation for heart in this cardiology conference. The conference is focalize on topics like clinical cardiology, coronary artery atherosclerosis, atherosclerosis risk factors, atherosclerosis aneurysm, lipoproteins and lipid transport, atherosclerosis therapeutics, hypertension, plaque hardens and narrows arteries  and many more…

The Atherosclerosis 2016 will be organized around the theme “Atherosclerosis: It's About More Than Heart Disease ".

2nd Annual Conference on Atherosclerosis, Vascular Biology and Thrombosis

May 01-03, 2017 Toronto, Canada

Theme: Atherosclerosis: It’s About More Than Heart Disease

Atherosclerosis is a specific form of arteriosclerosis in which an artery wall thickens as a result of invasion and accumulation of white blood cells (WBCs) (foam cell) and proliferation of intimal smooth muscle cell creating a fibro fatty plaque. Like water through a hose, blood flows through your arteries, delivering oxygen and nutrients to your organs. Atherosclerosis occurs when your arteries become clogged with fatty deposits (known as plaque), causing them to lose their elasticity and narrow. This blocks or slows the smooth passage of blood.

Plaque is a sticky, yellow substance made up of fatty materials such as cholesterol, calcium, and waste products from your cells. Atherosclerosis is a slow, progressive condition that may begin as early as childhood. It can occur anywhere in the body but usually affects large and medium-sized arteries. Atherosclerosis is asymptomatic for decades because the arteries enlarge at all plaque locations, thus there is no effect on blood flow. Even most plaque ruptures do not produce symptoms until enough narrowing or closure of an artery, due to clots, occurs.

Scope and Importance:

In 2010, cardiovascular, lung, and blood diseases accounted for 1,017,000 deaths and 41 % of all deaths in the United States. The estimated economic cost in 2009 for these diseases was $424 billion 23 % of the total economic costs of illness, injuries, and death. Of all diseases, heart disease is the leading cause of death; chronic lower respiratory diseases (CLRD), which includes COPD and asthma, ranks third (behind cancer); and cerebrovascular disease is fourth. Cardiovascular and lung diseases account for 3 of the 4 leading causes of death and 4 of the 10 leading causes of infant death. Hypertension, asthma, CHD, and COPD are especially prevalent and account for substantial morbidity in Cardiovascular Patients.

Why it’s in Toronto, Canada?

Atherosclerosis is a systemic disease affecting various vascular beds. It is the most important cause of angina, heart attack, peripheral vascular disease and stroke. Atherosclerosis and its thrombotic complications are currently the most important cause of morbidity and mortality in the developed world. In Canada there is a growing burden of cardiovascular diseases. These can be attributable to (Heart and Stroke Foundation of Canada, 2003).  Age is the most consistent risk factor for atherosclerosis. The proportion of population over the age of 65 years was 13% in 2001 and is expected to increase to 20% by the year 2025.

There is no cure for cardiovascular disease. As the underlying disease progresses, the events accumulate and so does the burden. Increasing adverse life style choices by the population like smoking, overeating and physical inactivity contribute to increasing the burden of the disease.

Eighty percent of the Canadian population has at least 1 modifiable risk factor for cardiovascular disease; nearly one-third has 2 risk factors; and another 11% have 3 or more.

More than one third (34.1%) of deaths in Canada in 2001 were due to cardiovascular events (Major chronic diseases surveillance online). Canadians lose 4.5 years of life expectancy due to cardiovascular diseases (Heart and Stroke Foundation of Canada, 2003). Coronary artery disease: This is the most common and most dangerous. Medically diagnosed heart disease is prevalent in 5.4% of Canadian men and 4.6% of Canadian women (Heart and Stroke Foundation of Canada, 2003). Ishaemic heart disease is secondary to atherosclerotic involvement of coronary arteries with or without thrombotic complications. Thus in 30-50% of patients, myocardial infarction is the index presentation, without any previous symptomatology. Peripheral vascular disease causes deaths, mainly secondary aortic aneurysms. 

Why to attend???

With members from around the world focused on learning about Cardiology and cardiovascular diseases, this is your single best opportunity to reach the largest assemblage of participants from the hospitals, universities, and organizations etc. This Annual Meeting will conduct demonstrations, distribute information, meet with current and potential researchers and receive name recognition at this event. World-renowned speakers, the most recent techniques, and the newest updates in this field are signet of this conference.

Universities/Organizations Associated with Atherosclerosis Research: 

In Toronto

• University of Toronto

• UHN Peter Munk Cardiac Centre 

• St. Michael's Hospital

• Lake Head University

• Carleton University

• Brock University

In Canada

• University of Toronto

• University of Ottawa

• Queen's University

• University of Guelph

• University of Western Ontario

• University of Manitoba

• McMaster University

Globally  

• National University, Singapore

• Oregon State University 

• Robart’s Research Institute, London

• The Scandinavian Society for Atherosclerosis Research (SSAR), Copenhagen

• The Thrombosis & Atherosclerosis Research Institute (TaARI), Ontario

• The University of Glasgow, Scotland, UK

• The University of Sydney, Australia

• The University of Vermont, Burlington

• University of California, San Francisco

• University of Colorado Boulder

• Ryerson University, USA

• University of Maryland Medical Centre, Baltimore

• University of Minnesota, Minneapolis 

• University of Nevada, Reno

• University of Southern California, Los Angeles

Societies of Atherosclerosis Globally:

• Canadian Society of Atherosclerosis, Thrombosis and Vascular Biology

• International Atherosclerosis Society

• European Atherosclerosis Society

• Australian Atherosclerosis Society

• British Atherosclerosis Society

• Czech Society for Atherosclerosis

• Diabetes Federation of Ireland

• German Atherosclerosis Society

• Heart and Stroke Foundation of Canada

• Canadian Cardiovascular Society

• Scandinavian Society for Atherosclerosis Research

• Society of Atherosclerosis Imaging

• Society for Vascular Surgery

Statistics of Cardiovascular Diseases & Atherosclerosis:

Remarkable progress has been made tackling cardiovascular disease in Canada over the past 60 years with death rates declining by more than 75 per cent. This has largely been due to research advances in surgical procedures, drug therapies and prevention effortsi. Yet despite our progress, heart disease and stroke remain leading causes of deathii and hospitalizationiii and the biggest driver of prescription drug use in Canadaiv.

An estimated 1.6 million Canadians are living with heart disease or the effects of a stroke.

  • 1.3 million Canadians are living with heart disease.
  • More than 400,000 Canadians are living with long-term stroke disability.
  • In 2012, more than 66,000 Canadians died from heart disease or stroke. That’s one person every 7 minutes.
    • In 2012, almost 14,000 Canadians died as the result of a heart attack.
    • In 2012, more than 13,000 Canadians died as the result of a stroke.
  • Each year more than 350,000 Canadians are hospitalized for heart disease or stroke.
  • In 2011, more than 305,000 Canadians were hospitalized for heart disease.
  • In 2011, more than 46,500 Canadians were hospitalized for stroke.
  • Heart disease and stroke costs the Canadian economy more than $20.9 billion every year in physician services, hospital costs, lost wages and decreased productivity.
  • By adopting healthy behaviours, you can delay the onset of heart disease or stroke by as much as 14 years.
  • Up to 80% of premature heart disease and stroke is preventable by adopting healthy behaviours.

Market Growth of Atherosclerosis Research in the last and upcoming ten years:

Heart disease affects whites and African Americans the most, accounting for 24.3 and 24.1 % of deaths, respectively. Asians and Pacific Islanders are at third-highest risk for a heart disease-related death, at 22.5 %. It accounts for 20.8 % of deaths in the Hispanic community, and 17.9 % in American Indians and Alaska Natives.

North America accounts for the largest cardiovascular devices market followed by Europe. This is due to increased awareness about various heart diseases, developed economies and increased overweight or obese people in the region. In addition, high disposable incomes and favorable reimbursement policies are also supporting the growth of cardiovascular devices market in the region. The U.S., followed by Canada, is the largest market for cardiovascular devices in North America. Germany, France and the U.K. are some of the largest markets for cardiovascular devices in the European region. However, Asia-Pacific represents the fastest growing region in the global cardiovascular devices market. This is due to increasing awareness about various heart diseases in the region and increasing number of aged people in the region.

In addition, high cost of cardiovascular devices and lack of skilled healthcare professionals to operate expensive devices also obstructs growth of cardiovascular devices. Rapid product launches and increasing mergers and acquisitions between cardiovascular devices manufacturing companies are key trends in global cardiovascular devices market.

Industries Globally for Cardiovascular & Atherosclerosis Research:

• AstraZeneca

• Care stream Health

• GlaxoSmithKline

• Intelomed

• Keystone Medical Technologies

• Sanofi

The top five countries with the lowest rates of heart disease deaths:  

• France

• Australia

• Switzerland

• Japan

• Canada

Advanced Atherosclerosis Techniques:

• Balloon angioplasty

• Coronary artery stenting

• Excimer laser angioplasty

• Intracoronary ultrasound

• Rotational, directional and trans luminal extraction atherectomy

Products manufactured by the industry related to Cardiology & Cardiovascular Diseases Research Globally:

• Pacemakers

• Implantable defibrillators Stents 

• Remote Patient Management.

• Vascular/Surgical Devices

• Small Molecules

• Heart valve corrective device & Stents 

• Specialized medicines

• Medical Diagnostic Instruments

• Single-use cardiovascular medical devices

Cardiovascular Market Research Reports & Industry Analysis:

Cardiovascular conditions can include angina, arrhythmia, atherosclerosis, congestive heart failure, coronary artery disease, hypertension, myocardial infarction or other disorders. All these diseases involve a malfunction of the heart or related circulatory system. Variations in heart size and position within the chest may be related to age, body size, shape, weight, or pathologic conditions of the heart and other nearby structures. There has been considerable study into the role of inflammation in heart disease. Researchers have found the first direct evidence that reducing inflammation in coronary arteries decreases the risk of heart attacks as much as reducing cholesterol levels. New drugs that target inflammation that are measured by a marker called C-reactive protein (CRP) could have a large impact on cardiovascular health as well as a large financial gain for companies developing these products.

Risk Prediction for Global CVD:

Whereas CHD is a major component of overall CVD, it does not include other important manifestations such as stroke, heart failure, and peripheral arterial disease. Framingham investigators have considered that for risk functions, a broader class of CVD components would be appropriate, especially for public health. In line with this in 2008, Framingham investigators presented a global CVD risk function for estimating the risk of developing any manifestations of CVD (including CHD, cerebrovascular disease, intermittent claudication, and congestive heart failure). The global CVD function produces an absolute risk estimate for global CVD and, by simple adjustments, the risk for any of the components of CVD. As an example, for a woman age 61 years, with HDL of 47, total cholesterol of 230, non-treated systolic blood pressure of 124, and who are a non-smoker and non-diabetic, the corresponding points are 9, 0, 3, 0, and 0 for a total of 12 points, which corresponds to a 10-year risk of CVD of 8.6%. For comparison, the ATP III function produces for this woman a 10-year risk of developing a hard CHD of 3%.

Atherosclerosis 2016

The Annual Conference on Atherosclerosis and Clinical Cardiology, Atherosclerosis 2016 was held in Philadelphia, USA during 11-12 July, 2016.

Atherosclerosis 2016 has received a substantial response from all over the world.  The Atherosclerosis 2016 has been conducted with the aim and the categorical intent of promoting the developments of new perceptions and ideas for exploring the high level of knowledge reached by scientific community in cardiology. The extremely illustrious conference hosted by OMICS International was marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing from different countries around the world. 

The conference aimed a parallel rail with theme “Advancements in management of Atherosclerosis”. The meeting engrossed a vicinity of cognizant discussions on novel aspects in the prevention, detection and treatment of atherosclerosis.

The two days event implanted a firm relation of upcoming strategies in the field of Clinical Cardiology with the scientific community. We are thankful to all our speakers for encouraging and supporting us to conduct the conference and propelling the same to reach the summit of success.

The Organizing Committee would like to thank the moderator Dr. Dennis I. Goldberg, LipimetiX Development, Inc, USA for his contributions which resulted in smooth functioning of the conference.

A series of invited lectures by Honorable guests and members of the Keynote Forum marked the commencement of the event. The prominent scientists in the field of atherosclerosis like Sampath Parthasarathy, University of Central Florida, USA; Yong-Jian Geng from University of Texas McGovern School of Medicine, USA   have left a mark with their presentations. The workshop entitled “Apolipoprotein E: A Therapeutic for Atherosclerosis and CVD's” under the leadership of  Dr. G.M. Anantharamaiah from UAB Medical Center, USA along with his colleagues Dr. Dennis I. Goldberg , Dr. Robert L. Raffai  and Dr. C. Roger White gave their fruitful contributions in the form of highly informative presentations at the conference. Dr. Bimal Chhajer from SAAOL Heart Center, India conducted a special session on prevention of the disease which was added as one of the star to the conference.

The guidance and support of the Organizing Committee Members also played a key role in the reaching the summit of success in the travel of this wonderful journey.

We once again thank you all the participants for their wonderful contribution towards the event which helped us for successful accomplishment of this event.

OMICS Annual Conference on Atherosclerosis and Clinical Cardiology would not have reached the pinnacle if not with the support of international, multi-professional steering committee and coordination of the Journal of Clinical & Experimental Cardiology, Atherosclerosis: Open Access, Journal of Cardiovascular Diseases & Diagnosis and International Journal of Cardiovascular Research; hence, we express our deep sense of gratitude.


Past Reports  Gallery  

Cardiology 2015

In the presence of inter professional researchers and practitioners involved in the development of high quality education in all aspects of clinical skills, OMICS 5th International Conference on Clinical & Experimental Cardiology was held during April 27-29, 2015 in Philadelphia, USA

OMICS Group played host to a diverse panel of key members of the Cardiology community from research lab, industry, academia and financial investment practices, discussing the future of Cardiology specialties. This event was really aimed for examining where the real cardiological specialties are going in the future and purpose of the event was to provide an opportunity for cross fertilization of ideas and development of ideas, in the field of Cardiology.

Focusing on Heart Diseases, Congenital Heart Diseases, Cardiac Therapeutic Agents, Biophysics and Systems Biology, Interventional Cardiology, Cancer and Heart, Current Research in Cardiology and Cardiac Surgery as well, the three days of discussions enabled professionals to gain an insight into the current innovations and opened up networking opportunities.

Cardiology-2015 Organizing Committee would like to thank the Moderators of the conference, Dr. Anastasia Susie Mihailidou, Royal North Shore Hospital & Kolling Institute, Australia and Dr. Mahazarin Ginwalla, University Hospitals Case Medical Center, USA who contributed a lot for the smooth functioning of this event.

We are also thank full to all the speakers who made this event a grand success, our special thanks to Stacy Masucci, Elsevier and Dr. John E. Strobeck, Daxor Corporation  for exhibiting at the conference, many thanks to all the media partners for the promotion of our event.

The highlights of the meeting were the eponymous lectures, delivered by Louis Samuels from Thomas Jefferson University School of Medicine, The Lankenau Heart Institute, USA, Anthony Martin Gerdes from New York Institute of Technology-College of Osteopathic Medicine, USA, Kate M Denton from Monash University, Australia, Yoshiaki Omura from New York Medical College, Heart Disease Research Foundation, USA, Robert M Mentzer from Wayne State University School of Medicine, USA, Karlheinz Seidl from Klinikum Ingolstadt GmbH, Germany. These talks were of great interest to the general cardiologists and were enormously informative.

OMICS 5th International Conference on Clinical & Experimental Cardiology was a great success with the support of international, multiprofessional steering committee and coordinated by the Journal of Clinical & Experimental Cardiology, Journal of Cardiovascular Diseases & Diagnosis and Cardiovascular Pharmacology: Open Access.


Past Reports  Gallery  

Cardiology-2014

In the presence of inter professional researchers and practitioners involved in the development of high quality education in all aspects of clinical skills, OMICS 4th International Conference on Clinical & Experimental Cardiology was held during April 14-16, 2014 in San Antonio, USA

OMICS Group played host to a diverse panel of key members of the Cardiology community from research lab, industry, academia and financial investment practices, discussing the future of Cardiology specialties. This event was really aimed for examining where the real cardio logical specialties are going in the future and purpose of the event was to provide an opportunity for cross fertilization of ideas and development of ideas, in the field of Cardiology.

Focusing on Heart Diseases, Congenital Heart Diseases, Cardiac Therapeutic Agents, Biophysics and Systems Biology, Interventional Cardiology, Cancer and Heart, Current Research in Cardiology, and Cardiac Surgery as well, the three days of discussions enabled professionals to gain an insight into the current innovations and opened up networking opportunities.

Cardiology-2014 Organizing Committee would like to thank the Moderator of the conference, Dr. Anastasia Susie Mihailidou, Royal North Shore Hospital, Australia who contributed a lot for the smooth functioning of this event.

The highlights of the meeting were the eponymous lectures, delivered by Louis Samuels, Thomas Jefferson University School of Medicine, USA, Richard J. Frink, Heart Research Foundation of Sacramento, USA, Bradley Field Bale, Bale/Doneen Method, USA, Karlheinz Seidl, Klinikum Ingolstadt, Germany. These talks were of great interest to the general cardiologists and were enormously informative.

OMICS 4th International Conference on Clinical & Experimental Cardiology was a great success with the support of international, multiprofessional steering committee and coordinated by the Journal of Clinical & Experimental Cardiology, Journal of Cardiovascular Diseases & Diagnosis.


Past Reports  Gallery  

Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date May 01-03, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Conferenceseries Destinations